Although Vertex (NASDAQ:VRTX) is still up 20% for the year as a whole, it dropped by about a fifth of its share price in November. The stock has been hit twofold. Results keep pouring in from both Abbott Labs' (NYSE:ABT) and Gilead's (NASDAQ:GILD) next generation hepatitis-C drug cocktails, with tremendous cure rates and without requiring the use of interferon -- you start to see the problem for Vertex's Incivek. Furthermore, quarterly results had sales of its cystic fibrosis drug coming in light of estimates, but international expansion should accelerate its growth. Watch and find out what David Williamson thinks about Vertex's month and what the future holds for the stock.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Why Vertex Lost in November
NASDAQ: VRTX
Vertex Pharmaceuticals

With the new generation of hepatitis-C drugs delivering incredible cure rates, Vertex's Incivek is getting outpaced.
David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of Vertex Pharmaceuticals. Motley Fool newsletter services recommend Gilead Sciences and Vertex Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.